Glenmark licenses oncology products from US-based APC Therapeutics

Glenmark Pharmaceuticals has entered into a licensing agreement with Boston-based APC Therapeutics Inc, a biopharmaceutical company focused on building a portfolio of best-in-class immuno-oncology (IO) therapies, for exclusive rights to a small molecule, oncology compound based on Antigen Presenting Cell (APC) biology. The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

“This asset adds to our robust biologics pipeline of targeted IO therapies. The mechanism of action of APC biology is very intriguing and has the potential to be transformative in cancer treatment by triggering powerful